STOCK TITAN

Moderna - MRNA STOCK NEWS

Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.

About Moderna

Moderna, Inc. is a commercial-stage biotechnology company renowned for pioneering messenger RNA (mRNA) therapeutics, a revolutionary in vivo drug modality that enables the body’s cells to produce human proteins and antibodies. This groundbreaking approach has transformed how medicines are developed, offering novel treatment avenues for infectious diseases, oncology, rare genetic disorders, and other serious conditions. By harnessing its proprietary mRNA platform, Moderna has established a comprehensive portfolio of potential therapeutics and vaccines, positioned at the nexus of science, technology, and healthcare innovation.

Innovative mRNA Technology Platform

The company’s core technology leverages synthetic mRNA to instruct patient cells to express therapeutic proteins. This innovative platform addresses traditionally undruggable targets and provides a versatile alternative to conventional therapies. With an extensive intellectual property estate that encompasses numerous patent applications and claims across novel nucleotide chemistries and drug compositions, Moderna’s expertise underpins its robust research and development pipeline. Its approach emphasizes rapid development, scalability, and the flexibility to target a wide array of disease conditions.

Clinical Pipeline and Therapeutic Areas

Moderna’s diversified clinical pipeline spans multiple therapeutic categories, including:

  • Infectious Diseases: The company gained widespread recognition for its development of an effective COVID-19 vaccine, which validated its mRNA technology on a global stage. It continues to evolve its respiratory vaccine portfolio with candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and other emerging infectious pathogens.
  • Oncology: Moderna is exploring mRNA-based immunotherapies designed to harness the immune system’s potential to target cancer cells, including individualized neoantigen therapies. These therapeutic approaches aim to offer precision treatment modalities in oncology.
  • Rare Diseases: The company’s strategy includes developing mRNA-based treatments for rare genetic disorders, where traditional drug modalities often fall short. By targeting metabolic disorders and other conditions with limited treatment options, Moderna is working toward addressing significant unmet medical needs.
  • Latent and Other Diseases: Beyond infectious and oncological applications, Moderna’s pipeline incorporates next-generation vaccines and therapeutics targeting latent viruses and other challenging medical conditions.

Market Position and Value Proposition

Positioned as a trailblazer in mRNA therapeutics, Moderna combines a deep understanding of biological mechanisms with advanced pharmaceutical science. Its core value proposition lies in the ability to quickly design and develop mRNA-based candidates, reducing both development timelines and manufacturing complexity relative to traditional modalities. This agility has not only provided a rapid response to emergent global health challenges but has also established the company as a significant player in the biotechnology sector.

Business Model and Operational Excellence

Moderna generates revenue through its commercialized vaccine products and ongoing clinical collaborations across various therapeutic areas. The company’s operational model is characterized by strategic partnerships, efficient research and development processes, and rigorous adherence to regulatory standards. Its focus on cost efficiencies and portfolio prioritization further enhances its competitive edge. This balanced approach underscores Moderna’s commitment to delivering innovative, scalable, and safe mRNA medicines.

Commitment to Scientific Rigor and Transparency

Underpinned by a culture of scientific excellence and continuous innovation, Moderna maintains a high standard of transparency and rigor in its research. The company’s clinical development programs are structured to provide clear evidence of safety and efficacy, supporting its authority in the biotech field. This commitment enables healthcare providers and analysts to gain a deep understanding of the interconnected dynamics within its research and development initiatives.

Summary

In summary, Moderna stands at the forefront of the mRNA revolution, with a proven platform that redefines traditional therapeutic approaches. Its comprehensive pipeline, covering infectious diseases, oncology, rare disorders, and beyond, is a testament to the transformative potential of mRNA technology. As a company deeply embedded within the biopharmaceutical landscape, Moderna continues to drive innovation, operational excellence, and advancements in patient care, reinforcing its role as a key contributor to the future of medicine.

Rhea-AI Summary

Moderna (MRNA) announces that its COVID-19 vaccine, mRNA-1273, remains highly effective against the Delta variant. A study involving 352,878 vaccinated individuals indicated an effectiveness rate of 87% against COVID-19 diagnosis and 96% against hospitalization. An analysis of their Phase 3 COVE study revealed a 36% reduction in breakthrough infections for those vaccinated more recently compared to those vaccinated earlier. The company advocates for a booster dose to enhance immunity and will share findings in a conference call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Moderna, Inc. (NASDAQ: MRNA) has made significant advancements in its mRNA vaccine pipeline, as announced during its fifth annual R&D Day. Key highlights include the development of a combination respiratory vaccine for COVID-19 and flu, and a pediatric vaccine for RSV and hMPV. Interim Phase 1 data showed boosted neutralizing antibody titers in older adults for the RSV candidate. Additionally, a personalized cancer vaccine trial is fully enrolled. Moderna currently has 37 programs in development, including 22 in clinical studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.81%
Tags
none
-
Rhea-AI Summary

Moderna, Inc. (MRNA) has partnered with National Resilience, Inc. to manufacture mRNA for its COVID-19 vaccine. This multi-year agreement will utilize Resilience's facility in Mississauga, Ontario, ensuring global distribution of the vaccine. The collaboration aims to broaden access to Moderna's vaccines and enhance pandemic response capabilities. Additionally, Moderna has initiated a collaboration with Canada to establish a state-of-the-art mRNA manufacturing facility, further solidifying its commitment to expanding healthcare solutions against respiratory viruses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
covid-19
Rhea-AI Summary

National Resilience, Inc. and Moderna, Inc. have entered a multi-year agreement for the manufacturing of mRNA for the Moderna COVID-19 vaccine. The mRNA will be produced at Resilience's facility in Mississauga, Ontario, for global distribution. Resilience's CEO, Rahul Singhvi, highlighted the impact of Moderna’s vaccine in saving lives and expressed excitement about this partnership, which aims to enhance vaccination efforts worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
covid-19
-
Rhea-AI Summary

Moderna has announced a collaboration with the Institute for Life Changing Medicines (ILCM) to develop an mRNA therapy, mRNA-3351, for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare genetic disorder affecting about 70-100 individuals globally. This partnership aims to provide the therapy free of charge to patients. Moderna will license mRNA-3351 to ILCM without upfront fees, and ILCM will handle clinical development, projected to start in 2022. This initiative reflects Moderna's commitment to addressing rare diseases without imposing high costs on patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
none
-
Rhea-AI Summary

Moderna, Inc. (Nasdaq: MRNA) has submitted a request for conditional marketing approval to the European Medicines Agency (EMA) for its COVID-19 vaccine booster dose, mRNA-1273, at a 50 µg level. The amended Phase 2 study involving 344 participants showed that this booster significantly increases antibody responses, particularly against the Delta variant, boosting neutralizing titers above Phase 3 benchmarks. The safety profile after the third dose was similar to that of the second dose, indicating the potential for effective ongoing immunity against COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
covid-19
Rhea-AI Summary

Moderna (NASDAQ: MRNA) announced participation in two virtual investor conferences on September 10, 2021. The Wells Fargo 2021 Virtual Healthcare Conference will begin at 10:00 a.m. ET, followed by the Morgan Stanley 19th Annual Global Healthcare Conference at 11:45 a.m. ET. Live webcasts can be accessed on the Moderna Investors website and will be available for replay for 30 days. Moderna has emerged as a leader in mRNA therapeutics, developing vaccines and treatments across various therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
conferences
-
Rhea-AI Summary

Moderna (NASDAQ:MRNA) has submitted data to the FDA for a booster dose of its COVID-19 vaccine (mRNA-1273) at a 50 µg dose level. The submission is backed by Phase 2 study data showing significant antibody responses against the Delta variant, exceeding benchmarks. Following the booster, neutralizing antibody titers increased significantly, especially in older adults. The safety profile remained consistent with previous doses. Moderna plans to submit further data to the EMA and other global authorities soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
covid-19
-
Rhea-AI Summary

Moderna has completed its Biologics License Application (BLA) for the COVID-19 vaccine, requesting Priority Review from the FDA. The final analysis of the Phase 3 COVE study shows the vaccine has a 93% efficacy rate, which remains durable for six months after the second dose. This marks the first BLA submission in Moderna's history. The company aims for full licensure to prevent COVID-19 in individuals aged 18 and older. The vaccine has been available under Emergency Use Authorization since December 2020 and has delivered over 300 million doses to the U.S. government.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
covid-19
Rhea-AI Summary

Moderna, Inc. (NASDAQ: MRNA) will host its fifth annual virtual R&D Day for analysts and investors on September 9 at 8:00 a.m. ET. Key presentations will be made by CEO Stéphane Bancel, Chief Medical Officer Paul Burton, and other leaders, focusing on Moderna's clinical development pipeline. Registration for the event can be done here. The webcast will also be available on Moderna's investor website and archived for one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
conferences

FAQ

What is the current stock price of Moderna (MRNA)?

The current stock price of Moderna (MRNA) is $27.16 as of April 1, 2025.

What is the market cap of Moderna (MRNA)?

The market cap of Moderna (MRNA) is approximately 10.6B.

What is Moderna's core technology?

Moderna uses a pioneering mRNA platform that instructs patient cells to produce therapeutic proteins, offering a new in vivo drug modality.

Which therapeutic areas does Moderna focus on?

Moderna’s portfolio spans infectious diseases, oncology, rare genetic disorders, and other conditions where traditional therapies may not be effective.

How does Moderna generate revenue?

Revenue is primarily generated through the commercialization of its vaccine products and strategic collaborations in the development of mRNA-based therapies.

What makes Moderna's mRNA platform unique?

The platform allows for rapid design and development of tailored therapeutics, addressing previously undruggable targets with innovative manufacturing processes.

How does Moderna maintain its competitive position?

Moderna leverages a robust intellectual property portfolio, strategic partnerships, operational efficiencies, and a strong clinical pipeline to maintain a competitive edge.

What is the significance of Moderna's COVID-19 vaccine?

The successful development and deployment of its COVID-19 vaccine validated the effectiveness of its mRNA technology, demonstrating its capability in quickly addressing global health challenges.

How does Moderna ensure safety and efficacy in its products?

Moderna adheres to rigorous clinical development protocols and regulatory standards, providing transparent and robust data from its extensive research and trials.

What are the future areas of focus for Moderna?

Moderna continues to enhance its pipeline in areas such as respiratory vaccines, cancer immunotherapies, and treatments for rare diseases, reinforcing its position in innovative medicine.
Moderna

Nasdaq:MRNA

MRNA Rankings

MRNA Stock Data

10.59B
358.52M
7.27%
72.77%
11.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE